Investor Alert: Investigation into Northwest Biotherapeutics, Inc. Announced by Holzer & Holzer, LLC
June 19 2014 - 2:11PM
Business Wire
Holzer & Holzer, LLC is investigating whether Northwest
Biotherapeutics, Inc. (“Northwest Bio” or the “Company”) (NASDAQ:
NWBO) and/or certain of its officers complied with the federal
securities laws in making public statements regarding its
experimental cancer vaccine, DCVax-Direct. On June 19, 2014,
TheStreet.com published a report in which Dr. Aman Buzdar is quoted
as criticizing Northwest Bio for issuing a series of public
statements regarding preliminary results of its ongoing
DCVax-Direct clinical trial. Dr. Buzdar is the vice president of
clinical research at MD Anderson, which is conducting the clinical
trial. The price of Northwest Bio stock has declined significantly
on the report.
If you recently purchased NWBO common stock and have suffered
loss on that investment, you are encouraged to contact Holzer &
Holzer, LLC and its attorney Marshall P. Dees, Esq. via email at
mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832,
to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that
dedicates its practice to vigorous representation of shareholders
and investors in litigation nationwide, including shareholder class
action and derivative litigation. More information about the firm
is available through its website, www.holzerlaw.com and upon
request from the firm. Holzer & Holzer, LLC has paid for the
dissemination of this promotional communication, and Corey D.
Holzer is the attorney responsible for its content.
Holzer & Holzer, LLCMarshall P. Dees, Esq., 888-508-6832
(toll-free)mdees@holzerlaw.com
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Sep 2023 to Sep 2024